Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Severe combined immunodeficiency due to CARD11 deficiency is a rare combined T and B cell immunodeficiency characterized by normal numbers of T and B lymphocytes, increased numbers of transitional B cells and hypo- to agammaglobulinemia, decreased numbers of regulatory T cells and defects in T-cell functions. It presents with severe susceptibility to infections, including opportunistic infections.
Features include always present findings: Decreased circulating immunoglobulin concentration, Agammaglobulinemia, Pneumocystis jirovecii pneumonia, and Decreased regulatory T cell proportion and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lungs and breathing | 2 | Pneumocystis jirovecii pneumonia, Recurrent respiratory infections |
CARD11 encodes caspase recruitment domain family member 11 (1,154 aa). Adapter protein that plays a key role in adaptive immune response by transducing the activation of NF-kappa-B downstream of T-cell receptor (TCR) and B-cell receptor (BCR) engagement. Highest expression in Cells EBV-transformed lymphocytes (65.8 TPM) and Spleen (55.0 TPM).
Severe combined immunodeficiency due to CARD11 deficiency is caused by mutations in the CARD11 gene on chromosome 7.
The CARD11 protein participates in RNF181 polyubiquinates BCL10 and Ub:UBE2D1,UBE2D2,UBE2D3, UBE2E1,UBE2N pathways.
CARD11 is classified as a druggable target (Clinically Actionable and Kinase categories) with score 0.0.
Genetic testing for CARD11 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for severe combined immunodeficiency due to CARD11 deficiency has been reported in the published literature.
Phenotype severity distribution: 8 always present features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for severe combined immunodeficiency due to CARD11 deficiency.
121 publications have been identified in PubMed for severe combined immunodeficiency due to CARD11 deficiency. Research spans Epidemiology / Natural History (26%), Review / Meta-Analysis (24%), and Basic Science / Preclinical (21%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 32 | 26% |
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 11:33 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Blood and immune system
2 |
Recurrent respiratory infections, Immunodeficiency |
Research summaries |
29 |
24% |
Laboratory research | 25 | 21% |
Patient case studies | 12 | 10% |
Clinical study results | 11 | 9% |
Testing and diagnosis research | 7 | 6% |
New treatment approaches | 5 | 4% |
GBD 2023 Child Growth Failure Collaborators (2026). [PMID: 41344792](https://pubmed.ncbi.nlm.nih.gov/41344792/). *Lancet Child Adolesc Health*. [Epidemiology / Natural History]
Fournier M (2026). [PMID: 42097138](https://pubmed.ncbi.nlm.nih.gov/42097138/). *Cell*. [Basic Science / Preclinical]
Wang W (2026). [PMID: 41942427](https://pubmed.ncbi.nlm.nih.gov/41942427/). *Signal Transduct Target Ther*. [Review / Meta-Analysis]
Gervais A (2026). [PMID: 41570068](https://pubmed.ncbi.nlm.nih.gov/41570068/). *Proc Natl Acad Sci U S A*. [Case Report / Case Series]
Lin KY (2026). [PMID: 41586588](https://pubmed.ncbi.nlm.nih.gov/41586588/). *Hum Vaccin Immunother*. [Epidemiology / Natural History]
Poisson L (2026). [PMID: 41964438](https://pubmed.ncbi.nlm.nih.gov/41964438/). *J Med Virol*. [Basic Science / Preclinical]
García-Martínez E (2025). [PMID: 40625738](https://pubmed.ncbi.nlm.nih.gov/40625738/). *Front Immunol*. [Review / Meta-Analysis]
AlYafie RS (2025). [PMID: 40275935](https://pubmed.ncbi.nlm.nih.gov/40275935/). *J Allergy Clin Immunol Glob*. [Case Report / Case Series]
Wang Z (2025). [PMID: 40446037](https://pubmed.ncbi.nlm.nih.gov/40446037/). *Sci Adv*. [Gene Therapy / Novel Therapeutics]
Chuleerarux N (2025). [PMID: 39859044](https://pubmed.ncbi.nlm.nih.gov/39859044/). *Medicina (Kaunas)*. [Review / Meta-Analysis]